Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Bristol-Myers Squibb Co. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Bristol-Myers Squibb Co., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term debt obligations
Accounts payable
Rebates and discounts
Income taxes
Employee compensation and benefits
Research and development
Dividends
Interest
Royalties
Current operating lease liabilities
Contingent value rights
Other
Other current liabilities
Current liabilities
Deferred income taxes
Long-term debt, excluding current portion
Income taxes
Pension and postretirement
Non-current operating lease liabilities
Deferred income
Deferred compensation
Contingent value rights
Other
Other non-current liabilities
Non-current liabilities
Total liabilities
Preferred stock, $2 convertible series, par value $1 per share
Common stock, par value of $0.10 per share
Capital in excess of par value of stock
Accumulated other comprehensive loss
Retained earnings
Cost of treasury stock
Total BMS shareholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Short-term Debt Obligations
There was an initial increase from 1.98% in 2020 to 4.53% in 2021 followed by a gradual decline to 2.21% by 2024, indicating a reduction in reliance on short-term debt as a portion of total liabilities and equity in later years.
Accounts Payable
Accounts payable consistently increased from 2.29% in 2020 to 3.89% in 2024, showing a growing share of payables relative to total liabilities and equity, possibly reflecting expansion or increased credit terms with suppliers.
Rebates and Discounts
This line increased steadily from 4.8% to 9.74%, more than doubling over five years, which might imply rising incentives or sales allowances impacting the company's obligations or revenue deductions.
Income Taxes (Current and Non-current)
Current income taxes rose from 0.55% to 1.63%, reflecting an increasing tax burden relative to total liabilities and equity. Conversely, non-current income taxes decreased substantially from 4.23% in 2020 to 1.61% in 2024, suggesting changes in deferred tax assets or liabilities over time.
Employee Compensation and Benefits and Research and Development
Both items showed moderate growth. Employee compensation climbed from 1.19% to 1.83%, while research and development increased from 1.20% to 1.48%, indicating sustained investment in workforce and innovation.
Dividends and Interest
Dividends increased steadily from 0.95% to 1.36%. Interest expense remained relatively stable around 0.33-0.37% but spiked to 0.62% in 2024, possibly reflecting higher debt costs or borrowings in that year.
Royalties and Operating Lease Liabilities
Royalties showed a modest rise from 0.39% to 0.52%. Current operating lease liabilities grew slightly from 0.14% to 0.20%, and non-current operating lease liabilities nearly doubled from 0.70% to around 1.48%, indicating increased lease commitments.
Other Current Liabilities and Current Liabilities Total
These liabilities grew significantly—other current liabilities rose sharply from 11.84% to 19.57%, while total current liabilities increased from 16.1% to 25.67%, suggesting elevated short-term obligations or accruals.
Deferred Income Taxes
There was a marked decline from 4.56% to 0.40%, denoting a reduction in deferred tax liabilities or assets.
Long-term Debt
Long-term debt remained stable near 36% from 2020 to 2022, increased modestly to 38.52% in 2023, then surged to a notable 51.41% in 2024, indicating substantial long-term debt accumulation in the last reported year.
Pension and Postretirement Liabilities
These liabilities saw a decrease from 0.76% to 0.43%, reflecting potentially reduced pension obligations or improved funding status.
Deferred Income and Deferred Compensation
Deferred income stayed relatively steady around 0.25-0.32%, while deferred compensation showed a slight increase from 0.29% to 0.49%.
Other Non-current Liabilities and Total Non-current Liabilities
Other non-current liabilities reduced from 6.56% to 4.83%, while overall non-current liabilities increased from 51.92% to 56.63%, driven primarily by long-term debt increases.
Total Liabilities
The total liabilities as a percentage of total liabilities and equity grew from 68.03% to 82.3%, indicating a heavier reliance on liabilities rather than equity over time.
Equity Components
Common stock and capital in excess of par increased steadily, with capital in excess of par rising from 37.41% to 49.7%, reflecting possible equity infusions or retained capital growth. Accumulated other comprehensive loss fluctuated slightly but remained a modest negative factor. Retained earnings increased substantially from 17.96% to 30.23% before dropping sharply to 16.10% in 2024, which might indicate dividend payments, losses, or other equity reductions in that year. The cost of treasury stock deepened negatively from -22.14% to -47.14%, suggesting notable share repurchases or treasury stock increases. Consequently, total shareholders’ equity decreased from 31.92% to 17.64% by 2024, consistent with higher liabilities and treasury stock impact.
Total Liabilities and Equity
Remained constant at 100% as expected since all items are expressed as percentages within this total.